CNS‐related subjective symptoms during treatment with beta 1‐ adrenoceptor antagonists (atenolol, metoprolol): two double‐blind placebo controlled studies.

Abstract

1 Whilst a number of studies have investigated whether metoprolol and atenolol, the most widely used 31-adrenoceptor antagonists, differ with regard to CNS-related subjective symptoms, few placebo-controlled studies using standardised questionnaires have been performed. 2 In the present report, the findings of two randomised, double-blind, cross-over studies in healthy volunteers are presented. The subjects were treated with placebo and atenolol (100 mg once daily) (Study 1) and metoprolol (100 mg once daily) and placebo (Study 2). 3 Subjective experiences were evaluated using a standardised instrument, the Minor Symptoms Evaluation-profile (MSE-profile), which was filled in 4, 8 and 24 h after intake of the tablets. A Type A questionnaire was also completed by the subjects.4 At 4 h both metoprolol and atenolol were found to affect negatively vitality and contentment, but these effects had declined after 8 h. A significant adverse effect on sleep was shown for atenolol compared with placebo, while no negative effect was observed for metoprolol. No significant differences were found in relation to Type A behaviour and P-adrenoceptor blockade. The number of subjects with Type A personality was, however, low. 5 The results of the studies indicate that the subjective symptoms of the Pl-adrenoceptor blockers are mild, and that the effects appear consistently with the recognised pharmacokinetic profiles of the two drugs.

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

“…The general adverse effects (AEs) of propranolol include nausea, vomiting, diarrhea, and other gastrointestinal symptoms. Severe adverse events include inhibition of cardiac function, Raynaud's phenomenon, aggravating bronchospasm, hyperkalaemia, depression, somnolence, and insomnia, which can result in serious consequences [2, 4–7]. At present, there are few reports on the risk factors of AEs in infants receiving oral propranolol; moreover, the long-term side effects of propranolol in infants are unknown [8, 9].…”

Factors predictive of functional outcomes in patients with fragility hip fracture

“…Bardage et al [47] demonstrated that hypertensive patients had signi cantly lower quality of life, with lower health-related quality of life (HRQL) and 36-item short form questionnaire (SF-36) scores. Previous studies explained that hypertensive individuals have reported lower social and psychological functioning [50,51] and have been associated with symptoms [52,53] and/or side effects of antihypertensive medication [54,55] such as headache, dizziness, depression, anxiety, and tiredness.…”

Quality of life assessment of treatment with dental appliance or UPPP in patients with mild to moderate obstructive sleep apnoea. A prospective randomized 1‐year follow‐up study

“…The MSE‐P was originally designed to measure CNS‐related symptoms in association with cardiovascular drugs ( Dahlöf et al . 1989 ; Dimenäs et al . 1989a , b).…”

“…Furthermore, contentment provides a measure of the impact of the treatment method on the individual. Although the questionnaire has been used in patients with hypertension and migraine ( Dimenäs et al . 1989a , b; Dahlöf and Dimenäs 1995 ) to our knowledge it has never been applied to patients with OSA.…”